{"TopicDetails": {"type": 0, "ccm2Id": 44835213, "cftId": 0, "identifier": "EU4H-2022-PJ-08", "title": "Call for proposals to develop early warning features and guidance in the area of pricing through the EURIPID database, based on competition cases", "publicationDateLong": 1644883200000, "callIdentifier": "EU4H-2022-PJ", "callTitle": "Action Grants 2022 - first wave", "callccm2Id": 44774006, "allowPartnerSearch": true, "workProgrammepart": {"id": 6515, "ccm_id": 45114455, "wp_part": "EU4H-2022", "wp_year": "EU4H-2022", "wp_title": "EU4H-2022"}, "frameworkProgramme": {"id": 43332642, "abbreviation": "EU4H", "description": "EU4 Health Programme (EU4H)"}, "programmeDivision": [{"id": 43332657, "abbreviation": "Health", "description": "Improving and fostering health in the Union to reduce the burden of communicable and non-communicable diseases"}, {"id": 43332653, "abbreviation": "EU4H-1", "description": "EU4H-1"}], "topicMGAs": [], "sme": false, "actions": [{"status": {"id": 31094503, "abbreviation": "Closed", "description": "Closed"}, "types": [{"typeOfAction": "EU4H-PJG EU4H Project Grants", "typeOfMGA": [{"id": 43326018, "abbreviation": "EU4H-AG", "description": "EU4H Action Grant Budget-Based"}]}], "plannedOpeningDate": "22 February 2022", "submissionProcedure": {"id": 31094504, "abbreviation": "single-stage", "description": "single-stage"}, "deadlineDates": ["24 May 2022"]}], "latestInfos": [], "budgetOverviewJSONItem": {"budgetTopicActionMap": {"3382182": [{"action": "EU4H-2022-PJ-08 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "22 February 2022", "deadlineModel": "single-stage", "deadlineDates": ["24 May 2022"], "budgetYearMap": {"2022": 300000}, "budgetTopicActionMap": {}}], "3382184": [{"action": "EU4H-2022-PJ-05 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "22 February 2022", "deadlineModel": "single-stage", "deadlineDates": ["24 May 2022"], "budgetYearMap": {"2022": 4000000}, "budgetTopicActionMap": {}}], "3382186": [{"action": "EU4H-2022-PJ-04 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "22 February 2022", "deadlineModel": "single-stage", "deadlineDates": ["24 May 2022"], "budgetYearMap": {"2022": 1000000}, "budgetTopicActionMap": {}}], "3382188": [{"action": "EU4H-2022-PJ-01 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "22 February 2022", "deadlineModel": "single-stage", "deadlineDates": ["24 May 2022"], "budgetYearMap": {"2022": 30000000}, "budgetTopicActionMap": {}}], "3382190": [{"action": "EU4H-2022-PJ-02 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "22 February 2022", "deadlineModel": "single-stage", "deadlineDates": ["24 May 2022"], "budgetYearMap": {"2022": 5000000}, "budgetTopicActionMap": {}}], "3382192": [{"action": "EU4H-2022-PJ-07 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "22 February 2022", "deadlineModel": "single-stage", "deadlineDates": ["24 May 2022"], "budgetYearMap": {"2022": 30000000}, "budgetTopicActionMap": {}}], "3382194": [{"action": "EU4H-2022-PJ-06 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "22 February 2022", "deadlineModel": "single-stage", "deadlineDates": ["24 May 2022"], "budgetYearMap": {"2022": 29000000}, "budgetTopicActionMap": {}}], "3382196": [{"action": "EU4H-2022-PJ-03 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "22 February 2022", "deadlineModel": "single-stage", "deadlineDates": ["24 May 2022"], "budgetYearMap": {"2022": 8000000}, "budgetTopicActionMap": {}}]}, "budgetYearsColumns": ["2022"]}, "description": "<SPAN class=\"topicdescriptionkind\">ExpectedOutcome</SPAN>:<p><strong><span><span><span style=\"color:black\">Background and policy context</span></span></span></strong></p><p><span><span><span style=\"color:black\">The Pharmaceutical Strategy for Europe mentions that the Commission will engage with Member States to foster transparency of price information to help them take better pricing and reimbursement decisions. Prices and pricing decisions influence access to cost-effective and affordable medicines. The 2019 report on the Competition enforcement in the pharmaceutical sector (2009-2017) revealed that the distortion of the price competition in the Union can affect the functioning of internal market. Voluntary collaborations on pricing, like the EURIPID database, can support early identification and warning for such practices through exchanges of relevant information at Union level.</span></span></span></p><p><span><span><span style=\"color:black\">This action will contribute to the policy priority to implement the Pharmaceutical Strategy for Europe as it concerns the support of Member States in national pricing and reimbursement policies. It implements the EU4Health Programme\u2019s general objective of improving the availability, accessibility and affordability of medicinal products and medical devices, and crisis-relevant products in the Union, and of supporting innovation regarding such products (Article 3, point (c)) through the specific objectives defined in Article 4, points (c) and (h), of Regulation (EU) 2021/522</span></span></span></p>\n<SPAN class=\"topicdescriptionkind\">Objective</SPAN>:<p><strong><span><span><span style=\"color:black\">Objectives pursued </span></span></span></strong></p><p><span><span><span style=\"color:black\">The scope of this action is to develop early warning mechanisms and guidance in the area of pricing through the EURIPID database, based on lessons from competition cases, in particular on excessive pricing</span></span></span><span><span><span style=\"color:black\">. </span></span></span></p><p><strong><span><span><span style=\"color:black\">Description of the activities to be funded under this topic</span></span></span></strong></p><p><span><span><span style=\"color:black\">This action will create common approaches to verify claims on price information and to provide appropriate guidance to adjust pricing methodologies.</span></span></span></p><p><span><span><span style=\"color:black\">The activities will include the monitoring of strategic sequencing of price increases of threats to de-list reimbursable medicines or withdraw of medicines. These activities may prevent price increases based on unfounded claims to recover investments and increased costs. </span></span></span></p>\n<SPAN class=\"topicdescriptionkind\">Scope</SPAN>:<p><strong><span><span><span style=\"color:black\">Expected results and impact</span></span></span></strong></p><p><span><span><span style=\"color:black\">This action will:</span></span></span></p><p><span><span><span style=\"color:black\">a) strengthen the cooperation between national authorities to address the challenges due to certain commercial practices; </span></span></span></p><p><span><span><span style=\"color:black\">b) extend the EURIPID database to develop warning features </span></span></span></p><p><span><span><span style=\"color:black\">c) develop relevant and related technical guidance; </span></span></span></p><p><span><span><span style=\"color:black\">d) provide an updated guidance document on External Reference Pricing.</span></span></span></p><p><strong><span><span><span style=\"color:black\">Specific mandatory deliverables and/or milestones</span></span></span></strong></p><p><span><span><span style=\"color:black\">The activities will include the monitoring of strategic sequencing of price increases meant to game the External Reference Pricing system and monitoring. </span></span></span></p><p><span><span><span style=\"color:black\">The extension of the EURIPID database to develop warning features is meant to identify strategic price increases and threats to de-list or withdraw medicines. As part of the activities, it would be necessary to explore synergies with other databases to complement early warning information (like verification of shortages and/or market withdrawals). </span></span></span></p><p><span><span><span style=\"color:black\">The following deliverables should be included: </span></span></span></p><ul level=\"0\"><li><span><span><span><em>Project Leaflet 1: </em>A leaflet (1-2 pages maximum) to promote the project must be produced at the beginning of the project</span></span></span></li><li><span><span><span><span><em>Leaflet 2: </em>A leaflet in A4 format (1-2 pages maximum) in a layman language (EN) to promote the output and the results of the project</span></span></span></span></li><li><span><span><span><em>Layman version of the Executive Summary of the Final Report: </em>This is a short (maximum 10 pages) version of the final report, written for the interested public as a target group.</span></span></span></li><li><span><span><span><span><em>Public Website </em><span style=\"color:black\">Expanded Project\u2019s website with the new features at </span><a href=\"https://www.euripid.eu\">https://www.euripid.eu</a></span></span></span></span></li><li><span><span><span><span><em>eLeaflets </em>on country background information on national pricing and reimbursement policies</span></span></span></span></li><li><span><span><span><span><em>Notification</em> feature on the updates of the list prices, price increases, updates on list of the products covered by their health insurance system etc</span></span></span></span></li><li><span><span><span><span><em>Webinars</em> for the users to strengthen cooperation to address certain commercial practices and to implement the guidance on pricing methods and ERP. </span></span></span></span></li><li><span><span><span><span><em>User guides: </em>updated user guides information, standardisation manual</span></span></span></span></li><li><span><span><span><span><em>Fact sheets:</em> analyses following the format \u2018EURIPID quick check\u2019 on specific products with data from the EURIPID database.</span></span></span></span></li><li><span><span><span><span><em>Dissemination activities</em>: meetings with EURIPID members and dedicated workshops with key stakeholders</span></span></span></span></li><li><span><span><span><span><em>Final report</em></span></span></span></span></li> </ul><p><strong><span><span><span style=\"color:black\">Specific action-level indicators for reporting purposes</span></span></span></strong></p><p><span><span><span style=\"color:black\">Applicants shall collect data on the following specific action-level indicators in their regular reporting activities in case of award:</span></span></span></p><ul level=\"0\"><li><span><span><span>Number of leaflets, factsheets, user guide and other communication materials disseminated</span></span></span></li><li><span><span><span>Number of notifications received by type (e.g. list prices, price increases, updates on list of the products covered by their health insurance system, etc)</span></span></span></li><li><span><span><span>Number of webinar and workshops and other dissemination activities organised</span></span></span></li><li><span><span><span>Number of participants to the webinar and workshop</span></span></span></li><li><span><span><span>Satisfaction rate of participants to the webinar and workshop</span></span></span></li><li><span><span><span>Number of additional warning integrated in the database</span></span></span></li><li><span><span><span>Number of countries uptaking ERP guidance document in their national processes</span></span></span></li><li><span><span><span>Number of countries declaring that Euripid has impacted their national pricing and reimbursement system of medicines</span></span></span></li><li><span><span><span>Number of countries providing information (on prices and reimbursement products; on sales data; on MEAs) </span></span></span></li> </ul><p><span><span><span style=\"color:black\">The applicants are required to include in their proposals additional specific action-level indicators which will be agreed with the Commission during the grant agreement preparation. </span></span></span></p><p><span><span><span style=\"color:black\">The Commission may require the awardees to collect data for additional specific action-level indicators, where needed to complement the above indicators.</span></span></span></p>\n", "conditions": "<p><b><span style=\"font-size: 12pt; line-height: 18.4px; color: rgb(64, 64, 64);\" lang=\"EN-US\">Conditions<br />\r\n</span></b></p>\r\n<p><b><span style=\"color:#404040;mso-themecolor:&#xA;text1;mso-themetint:191;mso-ansi-language:EN-US\" lang=\"EN-US\">1.&nbsp;</span></b><b><span lang=\"EN-US\">Admissibility conditions: </span></b><span lang=\"EN-US\">described in section 5 of the <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2022/call-fiche_eu4h-2022-pj_en.pdf\" target=\"_blank\">call document</a></span><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2022/call-fiche_eu4h-2022-pj_en.pdf\" target=\"_blank\">&nbsp;</a></p>\n<p><b><span lang=\"EN-US\">Proposal page limits and layout:</span></b><span lang=\"EN-US\">&nbsp;described in Part B of the Application Form available in the Submission System</span></p>\n<p><b><span lang=\"EN-US\">2. Eligible countries:&nbsp;</span></b><span lang=\"EN-US\">described in section 6 of of the<a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2022/call-fiche_eu4h-2022-pj_en.pdf\" target=\"_blank\"> call document</a></span></p>\n<p><b><span lang=\"EN-US\">3. Other eligibility conditions:</span></b><span lang=\"EN-US\">&nbsp;described in section 6 of the <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2022/call-fiche_eu4h-2022-pj_en.pdf\" target=\"_blank\">call document</a></span></p>\n<p><b>4. Financial and operational capacity and exclusion:&nbsp;</b>described in&nbsp;<span lang=\"EN-US\">section 7 of the <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2022/call-fiche_eu4h-2022-pj_en.pdf\" target=\"_blank\">call document</a></span></p>\n<p><b><span lang=\"FR-BE\">5.&nbsp;Evaluation and award:</span></b></p>\n<ul>\r\n    <li><b><span lang=\"EN-US\">Award criteria, scoring and thresholds:</span></b><span lang=\"EN-US\">&nbsp;described in section 9 of the <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2022/call-fiche_eu4h-2022-pj_en.pdf\" target=\"_blank\">call document</a></span></li>\r\n</ul>\n<ul>\r\n    <li><b><span style=\"color: rgb(64, 64, 64);\" lang=\"EN-US\">Submission and evaluation processes</span></b><b><span lang=\"EN-US\">:</span></b><span lang=\"EN-US\">&nbsp;described&nbsp;<span style=\"color: rgb(64, 64, 64);\">section 8 of the <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2022/call-fiche_eu4h-2022-pj_en.pdf\" target=\"_blank\">call document</a> and the</span>&nbsp;</span><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\"><span lang=\"EN-US\">Online Manual</span></a></li>\r\n</ul>\n<ul>\r\n    <li><b><span lang=\"EN-US\">Indicative timeline for evaluation and grant agreement:&nbsp;</span></b><span lang=\"EN-US\">described in section 4 of the <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2022/call-fiche_eu4h-2022-pj_en.pdf\" target=\"_blank\">call document</a></span></li>\r\n</ul>\n<p><b><span style=\"color: rgb(64, 64, 64);\" lang=\"EN-US\">6</span></b><b><span lang=\"EN-US\">. Legal and financial set-up of the grants:&nbsp;</span></b><span lang=\"EN-US\">described&nbsp;<span style=\"color: rgb(64, 64, 64);\">in section 10 of the <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2022/call-fiche_eu4h-2022-pj_en.pdf\" target=\"_blank\">call document</a></span></span></p>\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><b><span style=\"font-size: 12pt; line-height: 18.4px; color: rgb(64, 64, 64);\" lang=\"EN-US\">Documents<br />\r\n<br />\r\n<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"color:#404040;mso-themecolor:text1;mso-themetint:191;&#xA;mso-ansi-language:EN-US\" lang=\"EN-US\"><b><span lang=\"EN-US\">Call documents:</span></b></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"color:#404040;mso-themecolor:text1;mso-themetint:191;&#xA;mso-ansi-language:EN-US\" lang=\"EN-US\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2022/call-fiche_eu4h-2022-pj_en.pdf\" target=\"_blank\">Call document </a><o:p></o:p></span></p>\r\n<p><strong>EU4health standard application form</strong>:&nbsp;<a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/temp-form/af/af_eu4h_en.pdf\" target=\"_blank\">Standard application form</a><br />\r\n<strong>EU4Health detailed budget</strong>:&nbsp;<a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/reference-documents;programCode=EU4H\" target=\"_blank\">EU4Health Detailed budget table</a><br />\r\n<strong>EU4Health Programme</strong>:&nbsp;<a href=\"https://ec.europa.eu/health/funding/eu4health_en\" target=\"_blank\">EU4Health programme</a><br />\r\n<strong>EU4Health</strong>:&nbsp;<a href=\"https://ec.europa.eu/health/publications/2022-eu4health-work-programme_en\" target=\"_blank\">2022 Annual Work Programme</a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\">&nbsp;</p>\r\n<p>&nbsp;</p>\n<p><strong>EU4Health programme:</strong> <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/agr-contr/mga_eu4h_en.pdf\" target=\"_blank\">EU4Health&nbsp; MGA v1.0</a><br />\r\n<strong>EU4Health Regulation</strong>:  <a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021R0522\" target=\"_blank\">Regulation 2021/522</a><br />\r\n<strong>EU financial Regulation</strong>: <a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32018R1046&amp;qid=1535046024012\" target=\"_blank\">EU Financial Regulation 2018/1046</a></p>\r\n<p>&nbsp;</p>", "supportInfo": "<p><span style=\"font-family: Arial, sans-serif; font-size: 9pt;\">For help related to this</span><span style=\"font-family: Arial, sans-serif; font-size: 9pt;\">&nbsp;</span><b style=\"font-family: Arial, sans-serif; font-size: 9pt;\">call</b><span style=\"font-family: Arial, sans-serif; font-size: 9pt;\">, please contact:</span><span style=\"font-family: Arial, sans-serif; font-size: 9pt;\"> </span>HaDEA-HP-CALLS@ec.europa.eu </p>\r\n<p class=\"MsoNormal\" style=\"line-height: normal;\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/faq;grantAndTendertype=1;categories=p_submission_eval;programme=null;actions=;keyword=;period=null\"><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">Funding &amp; Tenders Portal FAQ</span></a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;&ndash; Submission of proposals.<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"line-height: normal;\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/helpdesks/contact-form\"><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">IT Helpdesk</span></a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;&ndash; Contact the IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"line-height: normal;\"><a href=\"https://webgate.ec.europa.eu/funding-tenders-opportunities/display/OM/Online+Manual\"><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">Online Manual</span></a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;&ndash; Step-by-step online guide through the Portal processes from proposal preparation and submission to reporting on your on-going project. Valid for all 2021-2027 programmes.</span></p>", "sepTemplate": "<p>To access the Electronic Submission Service, please click on the submission-button next to the <strong>type of action</strong> and the <strong>type of model grant agreement</strong> that corresponds to your proposal. You will then be asked to confirm your choice, as it cannot be changed in the submission system. Upon confirmation, you will be linked to the correct entry point.</p>\r\n<p>To access existing draft proposals for this topic, please login to the Funding &amp; Tenders Portal and select the My Proposals page of the My Area section.</p>", "links": [], "additionalDossiers": [], "infoPackDossiers": [], "callDetailsJSONItem": {"additionalInfo": "", "staticAdditionalInfo": "", "latestInfos": [{"approvalDate": "Oct 26, 2022 11:41:37 AM", "lastChangeDate": "Oct 26, 2022 11:41:37 AM", "content": "<p class=\"MsoNormal\"><span style=\"font-size:10.5pt;line-height:115%;font-family:&#10;&quot;inherit&quot;,serif;mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:&#10;Arial;color:#333333;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;&#10;padding:0cm;mso-ansi-language:EN-IE;mso-fareast-language:EN-IE\">A total of 41 </span><b><span style=\"font-size:10.5pt;line-height:115%;font-family:&quot;inherit&quot;,serif;&#10;mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Helvetica;&#10;color:#333333;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;&#10;padding:0cm;mso-ansi-language:EN-IE;mso-fareast-language:EN-IE\">proposals have been submitted&nbsp;</span></b><span style=\"font-size:10.5pt;line-height:115%;&#10;font-family:&quot;inherit&quot;,serif;mso-fareast-font-family:&quot;Times New Roman&quot;;&#10;mso-bidi-font-family:Arial;color:#333333;border:none windowtext 1.0pt;&#10;mso-border-alt:none windowtext 0cm;padding:0cm;mso-ansi-language:EN-IE;&#10;mso-fareast-language:EN-IE\">in response to this call.</span><span lang=\"EN-GB\"><o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2022-PJ-01: 6 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2022-PJ-02: 5 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2022-PJ-03: 6 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2022-PJ-04: 4 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2022-PJ-05: 1 proposal<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2022-PJ-06: 17 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2022-PJ-07: 1 proposal<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2022-PJ-08: 1 proposal<o:p></o:p></span></p>"}, {"approvalDate": "Feb 22, 2022 12:00:08 AM", "lastChangeDate": "Feb 22, 2022 12:00:08 AM", "content": "The submission session is now available for: EU4H-2022-PJ-06(EU4H-PJG), EU4H-2022-PJ-02(EU4H-PJG), EU4H-2022-PJ-03(EU4H-PJG), EU4H-2022-PJ-01(EU4H-PJG), EU4H-2022-PJ-05(EU4H-PJG), EU4H-2022-PJ-08(EU4H-PJG), EU4H-2022-PJ-04(EU4H-PJG), EU4H-2022-PJ-07(EU4H-PJG)"}], "hasForthcomingTopics": false, "hasOpenTopics": false, "allClosedTopics": true}}}